Published in J Pharmacokinet Pharmacodyn on February 22, 2008
Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis (2008) 1.64
Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet (2012) 1.53
Unexpected overestimation of methotrexate plasma concentrations: analysis of a single center pediatric population. Ther Drug Monit (2014) 1.38
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother (2008) 1.14
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother (2009) 1.14
Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit (2008) 1.09
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol (2009) 1.07
Impact of multiaccess infusion devices on in vitro drug delivery during multi-infusion therapy. Anesth Analg (2009) 1.00
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother (2011) 1.00
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol (2007) 0.98
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother (2010) 0.97
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet (2010) 0.96
Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother (2011) 0.96
Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol (2011) 0.95
Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant (2003) 0.95
Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. J Acquir Immune Defic Syndr (2011) 0.94
Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet (2012) 0.93
Chronobiology and anesthesia. Anesthesiology (2004) 0.92
Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. Curr Pharm Des (2015) 0.92
Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin Pharmacol Ther (2003) 0.90
Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. Crit Care (2009) 0.89
Circadian rhythms of oxidative phosphorylation: effects of rotenone and melatonin on isolated rat brain mitochondria. Chronobiol Int (2003) 0.89
Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol (2002) 0.88
Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol (2013) 0.87
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? Antimicrob Agents Chemother (2010) 0.87
Tubular transporters and clearance of adefovir. Eur J Pharmacol (2006) 0.86
Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis. Pain (2009) 0.86
Infusion set characteristics such as antireflux valve and dead-space volume affect drug delivery: an experimental study designed to enhance infusion sets. Anesth Analg (2010) 0.85
P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.85
Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 "Antalait" study. Ther Drug Monit (2014) 0.85
Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment. Antimicrob Agents Chemother (2009) 0.84
Biological rhythms: a neglected factor of variability in pharmacokinetic studies. J Pharm Sci (2008) 0.84
Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol (2011) 0.84
Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Pediatr Infect Dis J (2014) 0.84
Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit (2012) 0.83
Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.83
Which improvements could prevent the departure of the left-without-being-seen patients? Emerg Med J (2010) 0.83
Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir. Ther Drug Monit (2011) 0.82
Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother (2011) 0.82
A CT scan protocol for the detection of radiographic loosening of the glenoid component after total shoulder arthroplasty. Acta Orthop (2013) 0.82
The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease. Parkinsonism Relat Disord (2004) 0.81
A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Radiother Oncol (2010) 0.81
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol (2013) 0.81
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol (2010) 0.81
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults. J Acquir Immune Defic Syndr (2015) 0.80
Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology (2003) 0.80
Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet (2006) 0.80
[Tubular transporters OAT1 and MRP2 and clearance of adefovir]. Nephrol Ther (2005) 0.80
Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol (2012) 0.80
Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? Ther Drug Monit (2016) 0.80
The impact on drug mass flow rate of interrupting and resuming carrier fluid flow: an in vitro study on a very low dead-space volume infusion set. Anesth Analg (2011) 0.79
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients. Orphanet J Rare Dis (2011) 0.79
Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. Br J Pharmacol (2003) 0.79
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer (2012) 0.79
Effects of induced hyperthermia on pharmacokinetics of ropivacaine in rats. Fundam Clin Pharmacol (2009) 0.79
Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol Int (2010) 0.79
Cluster analysis: an alternative method for covariate selection in population pharmacokinetic modeling. J Pharmacokinet Pharmacodyn (2005) 0.78
A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients. AIDS (2013) 0.78
Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization. Ther Drug Monit (2016) 0.78
Efavirenz Concentrations and Probability of HIV Replication in Children. Pediatr Infect Dis J (2015) 0.78
Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. Fundam Clin Pharmacol (2006) 0.77
Effects of a seven-day continuous infusion of ropivacaine on circadian rhythms in the rat. Chronobiol Int (2006) 0.77
Poly-cyclodextrin functionalized porous bioceramics for local chemotherapy and anticancer bone reconstruction. J Biomed Mater Res B Appl Biomater (2013) 0.77
Chronopharmacokinetics of imipenem in the rat. Chronobiol Int (2007) 0.77
In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin. J Pharm Biomed Anal (2010) 0.77
Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. Antimicrob Agents Chemother (2013) 0.77
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther (2006) 0.76
Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother (2004) 0.76
Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf (2011) 0.76
Method for simultaneous measurement of norepinephrine, 3-methoxy-4-hydroxyphenylglycol and 3,4-dihydroxyphenylglycol by liquid chromatography with electrochemical detection: application in rat cerebral cortex and plasma after lithium chloride treatment. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.76
Intravenous abuse of methylphenidate. J Clin Psychopharmacol (2013) 0.76
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol (2004) 0.76
Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? Br J Clin Pharmacol (2014) 0.76
Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Br J Clin Pharmacol (2014) 0.75
Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam Clin Pharmacol (2013) 0.75
Use of extended-release methylphenidate (concerta) in treatment of cocaine dependence in a patient presenting with attention deficit hyperactivity disorder. J Neuropsychiatry Clin Neurosci (2014) 0.75
High variability in the exposure of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res (2013) 0.75
Time-of-day dependent pharmacodynamic and pharmacokinetic profiles of caffeine in rats. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.75
Modeling the effectiveness of nebulized terbutaline for decompensated chronic obstructive pulmonary disease patients in the emergency department. Medicine (Baltimore) (2016) 0.75
[Manufacturing waste of hemodialyzers decreases oxidative phosphorylation of mitochondria isolated from rats]. Nephrol Ther (2010) 0.75
Baclofen and risperidone association increases dramatically triglycerides level. Alcohol Alcohol (2013) 0.75
Effects of hyperthermia on pharmacokinetics of ertapenem in rats. Fundam Clin Pharmacol (2008) 0.75
Mussel inspired coating of a biocompatible cyclodextrin based polymer onto CoCr vascular stents. ACS Appl Mater Interfaces (2014) 0.75
Interaction of thiopental with esomeprazole in critically ill patients. Eur J Clin Pharmacol (2013) 0.75
Population pharmacokinetics of ertapenem in juvenile and old rats. Fundam Clin Pharmacol (2013) 0.75
[Pathological gambling and addiction to cannabis: common psychosocial profile?]. Soins Psychiatr (2014) 0.75
Review in pharmacokinetic models on corticosteroids. Mini Rev Med Chem (2006) 0.75
[Involvement of a public pharmacology laboratory in pharmacokinetic studies]. Therapie (2004) 0.75
Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer Drugs (2002) 0.75
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model. Eur J Gastroenterol Hepatol (2017) 0.75